# Neurocrine Biosciences is making a significant move into the realm of metabolic disorders with a $2.9 billion acquisition of Soleno Therapeutics.

*business · news · 2026-04-06 · Devdiscourse*

## Key points

- Neurocrine Biosciences is acquiring Soleno Therapeutics for $2.9 billion.
- The acquisition gives Neurocrine access to Vykat XR, approved for Prader-Willi syndrome in the U.S.
- Neurocrine is expanding its rare-disease treatment portfolio through this acquisition.
- Eli Lilly's Foundayo and Novo Nordisk's Wegovy pills are driving increased consumer demand for weight-loss medications.

**Companies:** Novo Nordisk, Eli Lilly, Neurocrine Biosciences, Soleno Therapeutics
**Countries:** United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/science-environment/3864023-neurocrines-strategic-expansion-americans-quest-for-convenient-weight-loss-solutions)

---

Canonical: https://newsio.io/n/48f01568-7549-4426-935a-604545043edf/neurocrine-biosciences-is-making-a-significant-move-into-the-realm-of-metabolic
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works